Email ID
Password
Scrip   
InterMune files pirfenidone for pulmonary fibrosis in US on mixed data
06 November 2009
Katie McQue

InterMune has filed its lead development candidate, pirfenidone, with the US FDA for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

IPF is a rare condition, affecting around 250,000 people in the US and EU combined. There are no medicines specifically approved in these...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36